Berlin - Delayed Quote EUR

OPKO Health Inc (XCY.BE)

1.1622

-0.0744

(-6.02%)

As of 8:08:28 AM GMT+2. Market Open.

Down -24.31% in 4 Weeks, Here's Why OPKO Health (OPK) Looks Ripe for a Turnaround

OPKO Health (OPK) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Zacks 5 hours ago

OPK
OPKO Health to Report First Quarter 2025 Financial Results on April 30, 2025

MIAMI, April 17, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three months ended March 31, 2025 after the close of the U.S. financial markets on Wednesday, April 30, 2025. OPKO’s senior management will provide a business update and discuss results as well as financial guidance during a conference call and live audio webcast on April 30th beginning at 4:30 p.m. Eastern time. CONFERENCE CALL & WEBCAST INFORMATION OPKO encourages p

GlobeNewswire 5 days ago

OPK
OPKO Health, Inc. (NASDAQ:OPK) boasts of bullish insider sentiment with 52% ownership and they have been buying lately

Key Insights OPKO Health's significant insider ownership suggests inherent interests in company's expansion The top 3...

Simply Wall St. 6 days ago

OPK
NextPlat Provides Statement on U.S. Tariff Impact on its E-Commerce Development Program

NextPlat Corp (NASDAQ: NXPL, NXPLW) ("NextPlat" or the "Company"), a global e-Commerce provider, today provided an update on the impact of current United States/China tariffs on its e-Commerce development program as a result of China's escalation in tariffs placed on US-produced goods imported into the country. This condition is expected to have a material impact on anticipated sales of US products into China.

PR Newswire 10 days ago

NXPL

NXPLW

OPK
OPKO Health Announces $100 Million Increase to its Existing Share Repurchase Program

MIAMI, April 04, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) today announced that its Board of Directors has authorized an increase of $100 million to the Company’s existing common stock repurchase program, bringing the aggregate capacity of the program to $200 million. Approximately $41 million of OPKO’s common stock has been repurchased under the existing program since its authorization in July 2024. “We believe OPKO’s shares continue to be significantly undervalued and offer an a

GlobeNewswire 18 days ago

OPK
Here's Why You Should Retain OPKO Health Stock in Your Portfolio

OPK's growth is fueled by Rayaldee's success and promising pipeline progress. However, margin pressure and overdependence on its lead product are concerning.

Zacks 25 days ago

OPK
Chairman & CEO of OPKO Health Phillip Frost Buys More Stock

Investors who take an interest in OPKO Health, Inc. ( NASDAQ:OPK ) should definitely note that the Chairman & CEO...

Simply Wall St. last month

OPK
Opko and Entera focus on oral care for obesity and metabolic disorders

Opko will hold 60% and Entera 40% ownership interests in the programme.

Pharmaceutical Technology last month

ENTX

OPK
OPKO Health and Entera Bio Enter into Collaboration Agreement to Advance Oral GLP-1/Glucagon Tablet Candidate into the Clinic to Treat Obesity and Metabolic Disorders

MIAMI and JERUSALEM, March 17, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) and Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptides and proteins replacement therapies, entered into a collaboration and license agreement to advance into the clinic the first oral dual agonist GLP-1/glucagon peptide as a once-daily tablet treatment for patients with obesity, metabolic and fibrotic disorders. The program combines OPKO’s proprietary long-acting oxyntomodulin analog

GlobeNewswire last month

OPK

ENTX
Tesla Stock Is Reaching a Breaking Point, Analyst Says. Plus, Vertical Aerospace, OPKO Health, and More.

We are maintaining our Buy rating on shares of Vertical Aerospace and our $13.50 price target. Vertical still boasts the second-largest aircraft backlog in the industry and remains the lone European survivor among electric vertical takeoff and landing, or eVTOL, competitors, providing the company an enviable competitive moat, considering that American competitors won’t be able to export initial FAA powered lift-certified aircraft to the region for some time. With the return of former (aircraft lessor) Avolon CEO Domhnal Slattery as chairman, we expect to see meaningful conversions of bankrupt competitors’ backlogs (particularly Lilium bizjet/luxury charter and airline shuttle customers) to Vertical’s backlog, which should ultimately result in an uptick in firm orders....It is apparent that the company will require additional capital that we have contemplated in our estimated discounted cash flow through 2035, which also includes revenue assumptions for aftermarket battery sales and service (Some 420 million pounds by 2035).

Barrons.com last month

TSLA

OPK

CXM
Is OPKO Health, Inc. (OPK) The Best Stock Under $3 to Buy Now?

We recently compiled a list of the 10 Best Stocks Under $3 to Buy Now. In this article, we are going to take a look at where OPKO Health, Inc. (NASDAQ:OPK) stands against the other stocks under $3. Investors are grappling with Trump-fueled stock market volatility in 2025. On March 12, 2025, Yahoo Finance reported […]

Insider Monkey last month

OPK
Labcorp is Set to Acquire Select Assets of BioReference Health of OPK

LH inks new agreement to acquire BioReference Health's oncology and related clinical testing services businesses.

Zacks last month

LH

OPK
Labcorp to acquire certain assets of Opko Health’s BioReference Health

Labcorp (LH) and OPKO Health (OPK) announced earlier on Tuesday that they have entered into an agreement for Labcorp to acquire select assets of BioReference Health, a wholly owned subsidiary of OPKO Health. Through this transaction, Labcorp will acquire BioReference Health’s laboratory testing businesses focused on oncology and oncology-related clinical testing services across the United States. This transaction includes certain customer accounts and other operating assets. When complete, the t

TipRanks last month

OPK

LH
Truist remains bullish on Labcorp after ‘another nice strategic acquisition’

Truist analyst David MacDonald notes Labcorp (LH) announced that the company has reached an agreement to acquire oncology-focused lab testing assets from BioReference Health (OPK) for $192.5M, with an additional earnout of up to $32.5M. The deal is expected to close in the second half of 2025, meets the company’s financial/strategic criteria and is expected to be accretive to earnings year one. The deal continues the strong M&A momentum from 2024, and Truist expects the additional BioReference a

TipRanks last month

OPK

LH
Labcorp Announces Acquisition of Select Assets of BioReference Health's Innovative Oncology and Related Clinical Testing Services Businesses

Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, and OPKO Health, Inc. (Nasdaq: OPK), a multinational biopharmaceutical and diagnostics company, announced today that they have entered into an agreement for Labcorp to acquire select assets of BioReference Health, a wholly owned subsidiary of OPKO Health.

PR Newswire last month

LH

OPK
Analyst Estimates: Here's What Brokers Think Of OPKO Health, Inc. (NASDAQ:OPK) After Its Annual Report

OPKO Health, Inc. ( NASDAQ:OPK ) just released its latest full-year results and things are looking bullish. Revenues...

Simply Wall St. last month

OPK
OPKO Health Full Year 2024 Earnings: Beats Expectations

OPKO Health ( NASDAQ:OPK ) Full Year 2024 Results Key Financial Results Revenue: US$713.1m (down 17% from FY 2023). Net...

Simply Wall St. last month

OPK
OPK Stock Gains Following Q4 Earnings Beat, Gross Margin Expands

The strength in OPKO Health's transfer of intellectual property and other revenues boosts its overall fourth-quarter 2024 performance despite lower RAYALDEE sales.

Zacks last month

OPK

RMD

CAH
Q4 2024 OPKO Health Inc Earnings Call

Q4 2024 OPKO Health Inc Earnings Call

Thomson Reuters StreetEvents last month

OPK

PFE

MRK
OPKO Health Inc (OPK) Q4 2024 Earnings Call Highlights: Strong Pharmaceutical Growth and ...

OPKO Health Inc (OPK) reports a return to profitability with significant pharmaceutical revenue growth and strategic collaborations.

GuruFocus.com last month

OPK

Performance Overview

Return	XCY.BE	S&P 500 (^GSPC)
YTD	-16.24%	-10.47%
1-Year	+3.71%	+5.09%
3-Year	-58.07%	+23.26%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

OPKO Health Inc (XCY.BE)

Down -24.31% in 4 Weeks, Here's Why OPKO Health (OPK) Looks Ripe for a Turnaround

OPKO Health to Report First Quarter 2025 Financial Results on April 30, 2025

OPKO Health, Inc. (NASDAQ:OPK) boasts of bullish insider sentiment with 52% ownership and they have been buying lately

NextPlat Provides Statement on U.S. Tariff Impact on its E-Commerce Development Program

OPKO Health Announces $100 Million Increase to its Existing Share Repurchase Program

Here's Why You Should Retain OPKO Health Stock in Your Portfolio

Chairman & CEO of OPKO Health Phillip Frost Buys More Stock

Opko and Entera focus on oral care for obesity and metabolic disorders

OPKO Health and Entera Bio Enter into Collaboration Agreement to Advance Oral GLP-1/Glucagon Tablet Candidate into the Clinic to Treat Obesity and Metabolic Disorders

Tesla Stock Is Reaching a Breaking Point, Analyst Says. Plus, Vertical Aerospace, OPKO Health, and More.

Is OPKO Health, Inc. (OPK) The Best Stock Under $3 to Buy Now?

Labcorp is Set to Acquire Select Assets of BioReference Health of OPK

Labcorp to acquire certain assets of Opko Health’s BioReference Health

Truist remains bullish on Labcorp after ‘another nice strategic acquisition’

Labcorp Announces Acquisition of Select Assets of BioReference Health's Innovative Oncology and Related Clinical Testing Services Businesses

Analyst Estimates: Here's What Brokers Think Of OPKO Health, Inc. (NASDAQ:OPK) After Its Annual Report

OPKO Health Full Year 2024 Earnings: Beats Expectations

OPK Stock Gains Following Q4 Earnings Beat, Gross Margin Expands

Q4 2024 OPKO Health Inc Earnings Call

OPKO Health Inc (OPK) Q4 2024 Earnings Call Highlights: Strong Pharmaceutical Growth and ...

Performance Overview